Transanal Endoscopic Microsurgery

The use of a local excision to treat patients with early rectal cancer is increasing these days [1]. Local excisions have been commonly used because they have the benefits of decreased postoperative morbidity and mortality, good functional outcome, and avoidance of the need for a stoma [2]. However, the use of a local excision, when compared with a radical resection, such as a low anterior resection and an abdominoperineal resection, for the treatment of patients with an early rectal malignancy remains controversial because of the variable oncologic outcomes [3]. Whether a local excision is an adequate approach to a curative resection of early rectal cancer has been a subject of much debate. A transanal excision (TAE) has been used for the treatment of patients with rectal tumors. A standard TAE is limited to tumors of less than 4 cm in diameter that lie within 6 to 8 cm of the anal verge, and it can be relatively difficult to use because it lacks precision and has poor visual quality. The TAE has benefits of having no significant learning curve or associated equipment cost. Transanal endoscopic microsurgery (TEM) was first introduced by Dr. Gerhard Buess in Germany in 1983. Now, TEM using a 40-mm operating proctoscope through which full-thickness excisions as high as 20 cm from the anal verge can be performed [4]. TEM is a minimally invasive technique involving an intraluminal excision of the rectal neoplasm with the use of instrumentation to maintain a stable pneumorectum, enabling a magnified view of the operating field. It also has multiple potential benefits over a TAE. TEM provides the potential benefits of an exceptionally good view of the whole rectum, precise dissection, and en bloc excisions of tumors located not only in the lower and the middle rectum, but also in the upper rectum. TEM also offers higher likelihood of achieving clear resection margins, less specimen fragmentation, and lower recurrence rates, but it is associated with a steep learning curve and requires expensive equipment. TEM has important roles in curative resections of early rectal adenocarcinomas (T1), as well as benign and carcinoid tumors, in histopathologic staging, and in palliative resections of advanced adenocarcinomas in patients medically unfit or unwilling to undergo a radical resection [5]. Some patients show a deterioration of the rectal continence function postoperatively because of the insertion of the 40-mm operating proctoscope. O’Neill et al. [6] suggested the following algorithm for the treatment of patients with rectal tumors by using TEM: T1N0 without adverse histologic features requires TEM alone; T1N0 with adverse features identified on final pathology requires TEM with postoperative chemoradiation (vs. radical resection); T2N0 requires neoadjuvant chemoradiation followed by TEM; T3 or N1 to N3 requires TEM, but only for medically unfit patients or patients who refuse radical surgery. Chemoradiotherapy remains an integral component of the multimodal treatment plan for the patients. Individuals with proximal rectal cancer, regardless of stage, often do well with a radical resection, so TEM is less likely to be used. Since 2009, transanal minimally invasive surgery (TAMIS) has been commonly used because it allows local excisions of rectal tumors to be performed through an anal port by using standard laparoscopic instruments. TAMIS may improve outcomes because of its being a meticulous surgical technique with an enhanced field of vision, infrequent specimen fragmentation, and lower positive margin rates [7]. Robotic-assisted TAMIS is feasible and safe for the local excisions of rectal tumors because of its allowing an increased field of vision and increased control of the robotic arm [8]. TAMIS provides potential advantages over TEM, but further comparative studies are needed to evaluate the advantages. The study that is the subject of this editorial enrolled 130 patients with rectal adenomas and early rectal cancer over a period of 6 years. The average tumor size was 2.8 ± 1.5 cm (range, 0.5 to 8.3 cm). One hundred two benign and 28 malignant tumors were removed. Of the latter, 23 were pT1 cancers and 5 were pT2 cancers. Two patients with pT2 cancer underwent adjuvant chemotherapy, 1 patient underwent an abdominoperineal resection, 1 patient refused further treatment, and one was lost to follow up. Correspondence to: Byung Chun Kim, M.D. Department of Surgery, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeongdeungpo-gu, Seoul 07441, Korea Tel: +82-2-829-5130, Fax: +82-2-849-4469, E-mail: [email protected]